Evidence map›Paper›PMID 34085536›Full record

ArticleJCO oncology practice2021

Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19.

Bobby Daly, Tara S Lauria, Jessie C Holland, Jericho Garcia, Jibran Majeed, Chasity B Walters, Melissa Zablocki, Kimberly Chow, Olga Strachna, Caitlin E Giles and 8 more

Open access · greenAbstract read
In one paragraph

Article in JCO oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Hospitalisation at Home of Patients with COVID-19: A Qualitative Study of User Experiences.International journal of environmental research and public health · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Bobby DalyMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6573-7650
Tara S LauriaMemorial Sloan Kettering Cancer Center, New York, NY.
Jessie C HollandMemorial Sloan Kettering Cancer Center, New York, NY.
Jericho GarciaMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7776-535X
Jibran MajeedMemorial Sloan Kettering Cancer Center, New York, NY.
Chasity B WaltersMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-3537-5227
Melissa ZablockiMemorial Sloan Kettering Cancer Center, New York, NY.
Kimberly ChowMemorial Sloan Kettering Cancer Center, New York, NY.
Olga StrachnaMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-4010-9671
Caitlin E GilesMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-8545-202X
Meghan F KellyMemorial Sloan Kettering Cancer Center, New York, NY.
Ashley HousenMemorial Sloan Kettering Cancer Center, New York, NY.
Maryanne CanavanMemorial Sloan Kettering Cancer Center, New York, NY.
Nina M MarescaMemorial Sloan Kettering Cancer Center, New York, NY.
Ray BaserMemorial Sloan Kettering Cancer Center, New York, NY.
Rori SalvaggioMemorial Sloan Kettering Cancer Center, New York, NY.
Mark E RobsonMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3109-1692
Diane L Reidy-LagunesMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2688-4556
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeOncology patients are vulnerable to adverse outcomes associated with COVID-19, and clinical deterioration must be identified early. Several institutions launched remote patient monitoring programs (RPMPs) to care for patients with COVID-19. We describe patients' perspectives on a COVID-19 RPMP at a National Comprehensive Cancer Center.

methodsPatients who tested positive for COVID-19 were eligible. Enrolled patients received a daily electronic COVID-19 symptom assessment, and a subset of high-risk patients also received a pulse oximeter. Monitoring was provided by a centralized team and was discontinued 14 days after a patient's positive test result and following 3 days without worsening symptoms. Patients who completed at least one assessment and exited the program were sent a patient engagement survey to evaluate the patient's experience with digital monitoring for COVID-19.

resultsThe survey was distributed to 491 patients, and 257 responded (52% completion rate). The net promoter score was 85%. Most patients agreed that the RPMP was worthwhile, enabled better management of their COVID-19 symptoms, made them feel more connected to their healthcare team, and helped prevent emergency room visits. Identified themes regarding patient-perceived value of a RPMP included (1) security: a clinical safety net; (2) connection: a link to their clinical team during a period of isolation; and (3) empowerment: an education on the virus and symptom management.

conclusionRPMPs are perceived to be of value to oncology patients with COVID-19. Policymakers should consider how these programs can be reimbursed to keep vulnerable patients at home and out of the acute care setting.

Indexed as

COVID-19NeoplasmsHumansMedical OncologyMonitoring, PhysiologicSARS-CoV-2

Identifiers

PMID34085536
PMCPMC8457795
OpenAlexW3165569418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.